AB Science is a late-clinical-stage company seeking to partner its asset masitinib, having phase 3 IND granted in Amyotrophic lateral sclerosis, progressives forms of multiple sclerosis, and mild Alzheimer's disease.

AB Science has developed two proprietary platforms. 

The first platform is based on masitinib, a highly selective protein kinase inhibitor in late-stage development for neurodegenerative diseases, oncology, and inflammatory diseases. 

The second platform is a portfolio of next-generation synthetic microtubule destabilizers including AB8939 (intravenous formulation) for hematology indications, currently in Phase 1, and a second compound (oral formulation) for sarcoma and solid tumors, which is close to entering regulatory pre-clinical development.